Hypoplastic Left Heart Syndrome Treatment Integrates Cardiac Stem Cells.

Initial trials of stem cell treatment for hypoplastic left heart syndrome have proven to be both safe and effective for children with the congenital defect.

Researchers from Okayama University have developed a method to treat the congenital heart defect known as hypoplastic left heart syndrome [HLHS] by utilizing a specialized cardiac stem cell.  In a Phase I clinical trial conducted on children suffering from HLHS, the scientists concluded that, because the young stem cells in children are more abundant and self-renewing than those in adults, intracoronary injection of stem cells is a safe and feasible approach to treating the condition. Continue reading